HIV vaccines in 2022: where to from here?-Reference-Cited by-同舟云学术

HIV vaccines in 2022: where to from here?

Published:2022-05 Issue:5 Volume:25 Page:
ISSN:1758-2652
Container-title:Journal of the International AIDS Society
language:en
Short-container-title:J Int AIDS Soc.

Author:

Hannah Stacey¹,Chinyenze Kundai²,Shattock Robin³,Yola Ntando⁴,Warren Mitchell¹^ORCID

Affiliation:

1. AVAC New York New York USA

2. IAVI Nairobi Kenya

3. Imperial College London London UK

4. Desmond Tutu Health Foundation and Advocacy for Prevention of HIV and AIDS (APHA) Cape Town South Africa

Publisher

Wiley

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jia2.25923

Reference6 articles.

1. Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition

2. Current approaches to HIV vaccine development: a narrative review

3. Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults

4. National Institutes of Health Press Release.HIV vaccine candidate does not sufficiently protect women against HIV infection. 31 August2021.

5. ResourceTracking for HIV Prevention R&D Working Group.2020.HIV prevention research & development investments.https://www.hivresourcetracking.org/investment‐by‐technology/. Accessed 20 April 2022.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD8+T-cell response to mutated HLA-B*35-restricted Gag HY9 and HA9 epitopes from HIV-1 variants from Medellin, Colombia;Heliyon;2024-06

2. Prophylactic HIV-1 vaccine trials: past, present, and future;The Lancet HIV;2024-02

3. Four Decades of HIV: Global Trends, Testing Assays, Treatment, and Challenges;Zoonoses;2024

4. Immune Response to HIV-1 Infection and Vaccine Development;Immunosuppression and Immunomodulation;2023-07-12

5. PrEP Scale-Up and PEP in Central and Eastern Europe: Changes in Time and the Challenges We Face with No Expected HIV Vaccine in the near Future;Vaccines;2023-01-04